Clinical trials: Lymphoid Hematological Malignancies
Advanced B-cell Lymphoid Malignancies
Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013)
This is a Phase 0/1 open-label, non-randomized, biomarker and pharmacodynamic study in patients with advanced B-cell lymphoid malignancies, including B-cell chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL)…
- Trial name
- NCT01888952
- Testing
- Prednisone, Roflumilast
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Anand B. Karnad
Acute Myelogenous Leukemia, Acute Lymphoid Leukemia
Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation
The goal of this study is to determine whether post-transplant consolidation with azacitidine combined with donor lymphocyte infusion (DLI) is a safe and effective approach for the prevention of relapse in pediatric and young…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphoid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT02458235
- Testing
- azacitidine, donor lymphocyte infusion
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, San Francisco
B-cell Follicular Lymphoma, B-cell Marginal Zone Lymphoma
Study of MLN8237 in Participants With Advanced Hematological Malignancies
This is an open-label, multicenter, phase 1 study of MLN8237 in participants with advanced hematological malignancies for whom there are limited standard treatment options.
- Conditions
- B-cell Follicular Lymphoma, B-cell Marginal Zone Lymphoma, Diffuse Large B-cell Lymphoma, B-cell Mantle Cell Lymphoma
- Trial name
- NCT00697346
- Testing
- Alisertib
- Where
- 10 sites in United States
- Volunteers
- 58 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Myeloproliferative Disorders, Leukemia
Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer
Rationale: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's…
- Conditions
- Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00295880
- Testing
- umbilical cord blood transplantation
- Volunteers
- 12 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Hematological Malignancies
Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen
In this study, participants with high-risk hematologic malignancies undergoing hematopoietic cell transplantation (HCT), who do not have a suitable human leukocyte antigen (HLA)-matched related/sibling donor (MSD), matched…
- Trial name
- NCT02199041
- Testing
- Cyclophosphamide, Thiotepa, Fludarabine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- St. Jude Children's Research Hospital
Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
This phase II trial studies how well nivolumab works for the treatment of hematological malignancies that have come back (relapsed), does not respond (refractory), or is detectable after CAR T cell therapy.
- Conditions
- Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma
- Trial name
- NCT04205409
- Testing
- Nivolumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Washington
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)
This phase II MATCH treatment trial identifies the effects of AZD4547 in patients whose cancer has genetic changes called FGFR gene alterations.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439240
- Testing
- FGFR Inhibitor AZD4547
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm
PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy
This phase II trial tests whether PEA works to relieve the symptoms of chemotherapy-induced peripheral neuropathy in patients with cancer.
- Conditions
- Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT05246670
- Testing
- Palmidrol, Quality-of-Life Assessment
- Where
- 10 sites in United States
- Volunteers
- 88 people
- Sponsor
- Academic and Community Cancer Research United
Lymphoma, Non-Hodgkin Lymphoma
Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies
Background: Non-Hodgkin lymphomas are blood cancers that can be difficult to treat. They can also return after treatment. Examples include diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphoma (PTCL).
- Conditions
- Lymphoma, Non-Hodgkin Lymphoma, NHL, Hematologic Malignancies
- Trial name
- NCT05371054
- Testing
- Vysis LSI MYC Break Apart Rearrangement Probe Kit, Venetoclax, VIP152
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)
This phase II MATCH treatment trial identifiesay block the protein tyrosine kinase WEE1 the effects of AZD1775 in patients whose cancer has a genetic change called BRCA mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439227
- Testing
- Adavosertib
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders
RATIONALE: Giving chemotherapy with or without total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00547196
- Testing
- filgrastim, Busulfan, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
RATIONALE: Giving chemotherapy and total-body irradiation (TBI) before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01076270
- Testing
- plerixafor, filgrastim, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Graft Versus Host Disease, Hematopoietic/Lymphoid Cancer
Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases
This pilot clinical trial studies donor stem cell transplant followed by cyclophosphamide in treating patients with hematological diseases.
- Trial name
- NCT02248597
- Testing
- fludarabine phosphate, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Wake Forest University Health Sciences
Leukemia, Acute, Chronic Myelogenous Leukemia (CML)
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells
Patients with hematologic malignancies will receive myeloablative chemotherapy followed by stem cell rescue with bone marrow or hematopoietic peripheral blood stem cells collected by apheresis from a filgrastim- (G-CSF)-mobilized…
- Conditions
- Leukemia, Acute, Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma (NHL)
- Trial name
- NCT01050764
- Testing
- Regulatory T-cells, Conventional T-cells, Melphalan
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Everett Meyer
Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML)
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies
Pilot Study Evaluating the Safety and Efficacy of a Co-Transplantation of NiCord®, a UCB-derived ex Vivo Expanded Population of Stem and Progenitor Cells with a Second, Unmanipulated CBU in Patients with Hematological Malignancies
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Non-Hodgkin's Lymphoma
- Trial name
- NCT01221857
- Testing
- NiCord®
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Gamida Cell ltd
Myeloablative Conditioning, HLA-mismatched Bone Marrow Transplantation
Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
This is a multi-institutional phase II haploidentical T cell replete bone marrow transplant (BMT) study in children with high-risk leukemia.
- Conditions
- Myeloablative Conditioning, HLA-mismatched Bone Marrow Transplantation, Graft Survival, Transplantation, Bone Marrow
- Trial name
- NCT02120157
- Testing
- Cyclophosphamide, TBI, Busulfan
- Where
- 9 sites in United States, Canada
- Volunteers
- 35 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chronic Myeloproliferative Disorders, Leukemia
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, and radiation therapy before a donor bone marrow transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00134004
- Testing
- cyclophosphamide, fludarabine phosphate, mycophenolate mofetil
- Where
- 3 sites in United States
- Volunteers
- 210 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Multiple Myeloma, AL Amyloidosis
COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies
To determine whether protective antibody levels increase after booster dosing with the Moderna COVID-19 vaccine in patients diagnosed with Hematologic Malignancies who have low antibody levels after a prior first vaccination with…
- Conditions
- Multiple Myeloma, AL Amyloidosis, Chronic Lymphocytic Leukemia
- Trial name
- NCT05028374
- Testing
- A single "booster" dose of the Moderna mRNA COVID-19 vaccine
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Acute Myeloid Leukemia, Diffuse Large B-cell Lymphoma
A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001)
The primary purpose of this study was to determine the recommended dose (RD) of birabresib (MK-8628) /OTX015 for further phase II studies, in participants with acute leukemia (AL) including acute myeloid leukemia (AML; de novo…
- Conditions
- Acute Myeloid Leukemia, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Multiple Myeloma
- Trial name
- NCT01713582
- Testing
- OTX015/Birabresib
- Volunteers
- 141 people
- Sponsor
- Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies
Recent studies of conventional chemotherapy for infants with high-risk hematologic malignancies show that the long-term disease-free survival is low.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplasia, Chronic Myeloid Leukemia
- Trial name
- NCT00145626
- Testing
- Chemotherapy and antibodies, Miltenyi Biotec CliniMACS, Allogeneic stem cell transplantation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- St. Jude Children's Research Hospital